Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion
Advancis (AVNC) Pacific Growth Gregory Wade Upgrade Overweight (from equal weight)
Wade believes AVNC will outperform its peers in anticipation of the start of the first Phase III trial of Pulsys amoxicillin, which is expected early next month. AVNC closed Friday at $8.30, down $0.36 on the week.
Amgen (AMGN)

Read the full 600 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers